Five-Year PHERGain Data Support Selective Chemotherapy Reduction, Not Broad Omission
Five-year PHERGain results support a PET- and pathology-guided strategy that spared some women with early HER2-positive breast cancer from chemotherapy. The phase 2 trial was not designed to prove equivalence with standard treatment, and its chemotherapy-free subgroup was defined after response became known.
Five-year results from the PHERGain trial strengthen the case for reducing chemotherapy in a carefully selected subset of women with early HER2-positive breast cancer. They do not show that chemotherapy can be removed from routine care for everyone with this disease.
The 30-second summary
- What happened? A planned five-year analysis followed a treatment strategy that used an early FDG-PET scan and the surgical pathology result to decide who could continue HER2-targeted therapy without chemotherapy.
- Why does it matter? Among 86 women who responded on PET, had no invasive cancer found at surgery and received no chemotherapy, five-year invasive disease-free survival was 92.4%.
- What is the catch? PHERGain was a non-comparative phase 2 trial. That 86-person subgroup was defined after treatment response was known, so its outcome cannot prove that chemotherapy omission caused an equivalent result.
Key Number: Five-year invasive disease-free survival was 89.5% in the 267-person adaptive-treatment surgery population, after a median 5.6 years of follow-up.
How the adaptive strategy worked
PHERGain enrolled women with operable stage I to IIIA HER2-positive breast cancer at 45 hospitals in seven European countries. Participants were assigned either standard chemotherapy with trastuzumab and pertuzumab, or an adaptive strategy that began with the two HER2-targeted medicines, with endocrine therapy when appropriate.
Women in the adaptive group received an FDG-PET scan after two cycles. Those whose tumors did not show the required metabolic response switched to chemotherapy. PET responders continued targeted therapy until surgery. If the removed tissue still contained invasive cancer, chemotherapy was added afterward; women with a pathological complete response could remain chemotherapy-free.
This matters because the strategy does not rely on one scan alone. It combines an early metabolic signal with direct examination of the tissue removed at surgery, creating two decision points before chemotherapy is omitted for the full treatment course.
What changed at five years
The earlier PHERGain analysis reported a three-year invasive disease-free survival rate of about 95% in the adaptive group. The newly published analysis extends follow-up to a median of 5.6 years. Among the 267 women in the adaptive surgery population, 26 experienced an invasive disease event or died within five years, producing an estimated five-year rate of 89.5%.
The most closely watched subgroup included 86 PET responders who achieved a pathological complete response and never received chemotherapy. Their estimated five-year invasive disease-free survival was 92.4%, with one distant recurrence. The confidence interval ranged from 86.7% to 98.5%, reflecting uncertainty around the estimate.
The standard-treatment group had an estimated rate of 96.7%, but the trial was not built for a formal comparison between groups. Its one-to-four allocation left a much smaller standard-treatment arm, which served mainly as an internal benchmark.
The blood-test signal remains exploratory
Researchers also studied circulating tumor DNA, or ctDNA, using stored blood samples. Detectable ctDNA before or during treatment was associated with poorer outcomes, while early clearance was associated with more pathological complete responses and better five-year survival. These analyses were exploratory, included missing samples and used a tumor-uninformed assay.
The finding suggests that a blood marker might eventually complement imaging and surgical pathology. It does not yet justify using ctDNA to remove or intensify treatment in routine practice. A prospective trial would need to assign care using the biomarker and show that the decision improves outcomes.
Before we overstate the result
The chemotherapy-free group was selected because its tumors had already responded well on PET and showed no invasive disease at surgery. It was not a randomized chemotherapy-versus-no-chemotherapy comparison. Some participants also did not re-consent for extended follow-up, which can introduce attrition bias. The study was funded by Roche, and Guardant Health funded the ctDNA analyses. These limitations do not erase the encouraging durability signal, but they prevent a broad claim that selected therapy is already equivalent to standard care.
What happens next
Longer follow-up and new comparative trials are needed to define which patients can safely receive less chemotherapy. Future designs may combine early PET response, pathological complete response and prospectively validated ctDNA measurements. For now, PHERGain supports response-adapted de-escalation as a research-backed strategy for specialist evaluation, not a general instruction to skip chemotherapy.
Verified topics and entities
Sources and citations4 sources
External references used to support the reporting in this article.
Published by
NewTqnia Health Desk
An institutional editorial team within NewTqnia
